Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Recipient : MoonLake Immunotherapeutics
Deal Size : Undisclosed
Deal Type : Termination
Details : MoonLake plans to execute on its development program to unlock the potential of Sonelokimab, the novel investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients with inflammatory diseases.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
April 05, 2022
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Recipient : MoonLake Immunotherapeutics
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Recipient : MoonLake Immunotherapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Proceeds from the transaction are expected to provide MoonLake with the capital needed to accelerate the development of the clinical stage, tri-specific Nanobody® sonelokimab, in multiple inflammatory diseases in dermatology and rheumatology driven by I...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : $230.0 million
October 04, 2021
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Recipient : MoonLake Immunotherapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : L-DOS47
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Moffitt Cancer Center
Deal Size : Undisclosed
Deal Type : Collaboration
Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration
Details : In this next stage, the Company together with Moffit, intends to build on these early successes and provide additional preclinical support in using L-DOS47 with immunotherapies as clinical support.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
August 12, 2020
Lead Product(s) : L-DOS47
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Moffitt Cancer Center
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : L-DOS47,Carboplatin,Pemetrexed
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Helix BioPharma Corp. L-DOS47 Phase I Lung Cancer Trial Data to be released at ASCO 2020
Details : Topline data of the recently completed L-DOS47 dose escalation study in combination with pemetrexed and carboplatin in recurrent or metastatic non-squamous non-small cell lung cancer will be published at the ASCO 2020 Annual Conference.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
May 14, 2020
Lead Product(s) : L-DOS47,Carboplatin,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable